We employ mass spectrometry imaging (MSI) to study a wide variety of processes occurring within any organ of interest as the result of various pathophysiological processes and drug delivery. MSI is a powerful tool for directly measuring the distribution of molecules in tissue sections. The uniqueness of this technique is that it enables a high-resolution outlook on how various substances distribute in organs at different time points without prior knowledge of their existence or employing fluorescent or radioactive labels. Hundreds of molecular species can be visualized at one step, which can reflect on the subtlest physiological processes triggered by pathological conditions or external intervention such as drug delivery. Particularly we strive to answer questions about metabolic changes accompanying disease progression, as well as their response to drug treatment. We aim to identify novel targets for therapeutic intervention, which may be crucial for disease initiation and progression. In addition, we use MSI to monitor drug delivery efficiency, such as tracking active pharmaceutical ingredient (API) release and distribution, revealing API and its carrier co-localization, their impact on disease progression and predisposing the target/adjacent organs to adverse effects, identification of treatment-predictive biomarkers and stratification of drug delivery. We are able to precisely map the changes in lipid, peptide and metabolite profiles, and co-localize them with the delivered drug, its metabolites and the carrying vehicle.
We employ mass spectrometry imaging (MSI) to study a wide variety of processes occurring within any organ of interest as the result of various pathophysiological processes and drug delivery. MSI is a powerful tool for directly measuring the distribution of molecules in tissue sections. The uniqueness of this technique is that it enables a high-resolution outlook on how various substances distribute in organs at different time points without prior knowledge of their existence or employing fluorescent or radioactive labels. Hundreds of molecular species can be visualized at one step, which can reflect on the subtlest physiological processes triggered by pathological conditions or external intervention such as drug delivery. Particularly we strive to answer questions about metabolic changes accompanying disease progression, as well as their response to drug treatment. We aim to identify novel targets for therapeutic intervention, which may be crucial for disease initiation and progression. In addition, we use MSI to monitor drug delivery efficiency, such as tracking active pharmaceutical ingredient (API) release and distribution, revealing API and its carrier co-localization, their impact on disease progression and predisposing the target/adjacent organs to adverse effects, identification of treatment-predictive biomarkers and stratification of drug delivery. We are able to precisely map the changes in lipid, peptide and metabolite profiles, and co-localize them with the delivered drug, its metabolites and the carrying vehicle.